Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma

References

• Passweg J, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant. 2016;51(6):786–792.
   Google Scholar
• Hoggatt J, Speth JM, Pelus LM. Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization. Stem Cells. 2013;31:2599–2606.
   PubMed Web of Science ®Google Scholar
• Bensinger W, DiPersion JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43:181–195.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010;150:647–662.
   PubMed Web of Science ®Google Scholar
• Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic stem cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20:1262–1273.
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua A, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yield for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–1056.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009;84:335–337.
   PubMed Web of Science ®Google Scholar
• Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic cells – definitions, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490–499.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Varmavuo V, Juutilainen A, et al. Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol. 2012;91:1073–1079.
   PubMed Web of Science ®Google Scholar
• Sancho JM, Morgades M, Grifols JR, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34[+] cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy. 2012;14:823–829.
   PubMed Web of Science ®Google Scholar
• Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331–338.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol. 2010;85:463–471.
   PubMed Web of Science ®Google Scholar
• De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer [Mozobil]. Biochem Pharmacol. 2009;77:1655–1664.
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728–2730.
   PubMed Web of Science ®Google Scholar
• Hubel K, Liles WC, Broxmeyer H, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR antagonist. Support Cancer Ther. 2004;1:165–172.
   PubMedGoogle Scholar
• Broxmeyer H, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR antagonist. J Exp Med. 2005;201:1307–1318.
   PubMed Web of Science ®Google Scholar
• Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011;71:162347.
   Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition. Transfus Apher Sci. 2012;46:257–262.
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Devine SN, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867–1874.
   PubMed Web of Science ®Google Scholar
• Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005 Mar;45(3):295–300.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer E, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Morris C, Sureda A, van Biezen A, et al. The EMA-directed plerixafor safety survey: the EBMT CALM study. Bone Marrow Transplant. 2011;46([Suppl.1]):S32.
   Google Scholar
• Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009;15:249–256.
   PubMed Web of Science ®Google Scholar
• Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. 2010;45:63–68.
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor [Mozobil] in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010;45:39–47.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Ho AD, Klein LM, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant. 2011;46(3):350–355. doi:10.1038/bmt.2010.
   Web of Science ®Google Scholar
• Russell N, Douglas K, Ho AD, et al. Plerixafor and granulocyte colony-stimulating factor for first line steady state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica. 2013;98:172–178.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Uberti J, Devine S, et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013;48:777–781.
   PubMed Web of Science ®Google Scholar
• Clark RE, Bell J, Clark JO, et al. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilization, and is effective even in heavily pretreated patients. Blood Cancer J. 2014;4:e255.
   PubMed Web of Science ®Google Scholar
• Jagirdar N, Harvey RD, Nooka A, et al. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a phase II clinical trial. Transfusion. 2015;55:2351–2357.
   PubMed Web of Science ®Google Scholar
• Schmid A, Friess D, Mansouri Taleghani B, et al. Role of plerixafor in autologous stem cell mobilization with vinorelbine and granulocyte colony stimulating factor in patients with myeloma: a phase II study [PAV] trial. Leuk Lymphoma. 2015;56:608–614.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Mikhael J, Laplant B, et al. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplant. 2014;49:201–205.
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:1095–1102.
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Comenzo R, Badel K, et al. Plerixafor [Mozobil] alone to mobilize hematopoietic cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant. 2010;16:695–700.
   PubMed Web of Science ®Google Scholar
• Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor [AMD3100] plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1253–1261.
   PubMed Web of Science ®Google Scholar
• Yuan S, Palmer JM, Tsai NC, et al. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor. Hematol Oncol. 2016 Feb 29. [Epub ahead of print].
   PubMedGoogle Scholar
• Micallef IN, Stiff PJ, Stadtmauer EA, et al. Safety of upfront plerixafor + G-CSF versus placebo +G-CSF for mobilization of CD34[+] hematopoietic progenitor cells in patients > 60 and < 60 years of age with non-Hodgkin’s lymphoma or multiple myeloma. Am J Hematol. 2013;88:1017–1023.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff PJ, DiPersio JF, et al. Successful stem cell remobilization using plerixafor [Mozobil] plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant. 2009;15:1578–1586.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Nademanee AP, Micallef IN, et al. Plerixafor plus granulocyte colony stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant. 2013;19:670–675.
   PubMed Web of Science ®Google Scholar
• Nademanee AP, DiPersio JF, Maziarz RT, et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34[+] hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34[+] cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant. 2012;18:1564–1572.
   PubMed Web of Science ®Google Scholar
• Basak GW, Knopinska-Posluszny W, Matuszak M, et al. Hematopoietic stem cell mobilization with reversible CXCR4 receptor inhibitor plerixafor [AMD3100] – Polish compassionate use experience. Ann Hematol. 2011;90:557–568.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Laszlo D, Rizzi S, et al. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res. 2011 Jun;35(6):712–714.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte G-CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant. 2011;46:52–58.
   PubMed Web of Science ®Google Scholar
• Hubel K, Fresen MM, Salwender H, et al. Plerixafor with or without chemotherapy for poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant. 2011;46:1045–1052.
   PubMed Web of Science ®Google Scholar
• Attolico I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allow adequate PBSC collected in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 2012;18:241–249.
   PubMed Web of Science ®Google Scholar
• Hubel K, Fresen MM, Apperley JR, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2012;47:1046–1050.
   PubMed Web of Science ®Google Scholar
• Lanza F, Lemoli R, Olivieri A, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey of 215 patients with multiple myeloma and lymphoma. Transfusion. 2014;54:331–339.
   PubMed Web of Science ®Google Scholar
• Sheppard D, Bredeson C, Huebsch L, et al. A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian special access program. Bone Marrow Transplant. 2014;49:751–755.
   PubMed Web of Science ®Google Scholar
• Kim JS, Yoon DH, Park S, et al. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor [G-CSF] in patients with malignant lymphoma or multiple myeloma previously failing with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Ann Hematol. 2016;95:603–611.
   PubMed Web of Science ®Google Scholar
• Malard F, Kröger N, Gabriel IH, et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine and lenalidomide. Biol Blood Marrow Transplant. 2012;18:314–317.
   PubMed Web of Science ®Google Scholar
• Chabannon C, Bijou F, Miclea JM, et al. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrated the predominant use of the ‘on-demand’ scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion. 2015;55:2149–2157.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Lemoli R. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion. 2012;52:906–914.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013;19:87–93.
   PubMed Web of Science ®Google Scholar
• Sinha S, Gastineau D, Micallef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant. 2011;46:943–949.
   PubMed Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cell mobilization and harvest with no increase in costs. Br J Haematol. 2014;164:113–123.
   PubMed Web of Science ®Google Scholar
• Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014 Jul;49(7):865–872.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant. 2011;17:729–736.
   PubMed Web of Science ®Google Scholar
• Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of ’just in time’ salvage plerixafor administration in autologous transplant patients with poos stem cell mobilization kinetics. Transfusion. 2011;51:2175–2182.
   PubMed Web of Science ®Google Scholar
• Kymes SM, Pusic I, Lambert DL, et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care. 2012;18:33–41.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Chao N, Shapiro J, et al. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transplant. 2013 Sep;19(9):1301–1309.
   PubMed Web of Science ®Google Scholar
• Hundemer M, Engelhardt M, Bruckner T, et al. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. J Clin Apher. 2014;29:299–04.
   PubMed Web of Science ®Google Scholar
• Hübel K, Azar N, Farina L, et al. Time and effort quantification of autologous peripheral blood stem cell mobilization: a European perspective. Bone Marrow Transplant. 2016;51(Suppl. 1s):abstractP763.
   Google Scholar
• Martin AP, Richards S, Haycox A, et al. Evaluating the use of plerixafor in stem cell mobilization – an economic analysis of the PHANTASTIC trial. J Clin Apher. 2015 Sept 29. [Epub ahead of print]
   Web of Science ®Google Scholar
• Varmavuo V, Silvennoinen R, Anttila P, et al. Cost analysis of a randomized stem cell mobilization study in multiple myeloma. Submitted 2016.
   Google Scholar
• Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplant outcomes. Biol Blood Marrow Transplant. 2010;16:1629–1648.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant. 2011;46:627–635.
   PubMed Web of Science ®Google Scholar
• Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007;7:315–317.
   PubMedGoogle Scholar
• Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony stimulating factor [G-CSF] and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 2009;11:992–01.
   PubMed Web of Science ®Google Scholar
• Girbl T, Lunzer V, Greil R, et al. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cell mobilized by ‘on demand’ addition of plerixafor to granulocyte colony stimulating factor. Transfusion. 2014;54:2325–2335.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol. 2012;89:128–135.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Silvennoinen R, et al. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion. 2013;53:1024–1032.
   PubMed Web of Science ®Google Scholar
• Roug A, Hokland LB, Segel E, et al. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery. Cytotherapy. 2014;16:392–01.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Blood graft cellular composition and posttransplant recovery in non-Hodgkin’s lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion. 2015;55:2358–2368.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Blood lymphocyte subsets after plerixafor injection in non-Hodgkin’s lymphoma patients mobilizing with chemotherapy plus granulocyte-colony stimulating factor. Transfusion. 2012;52:1785–1791.
   PubMed Web of Science ®Google Scholar
• Zubair AC, Kao G, Daley H, et al. CD34[+]CD38[-] and CD34[+]HLADr[-] cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long –term hematopoietic reconstitution after autologous transplantation. Cytotherapy. 2006;8:1484–1493.
   Web of Science ®Google Scholar
• Gaugler B, Arbez J, Legouill S, et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy. 2013;15:861–868.
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin’s lymphoma patients. Stem Cells. 2007;16:657–666.
   Web of Science ®Google Scholar
• Varmavuo V, Rimpiläinen J, Kuitunen H, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin’s lymphoma patients. Transfusion. 2014;54:1243–1250.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Dougherty AL, Vogl DT, et al. Association between mobilization regimen and PFS after auto SCT for multiple myeloma. Bone Marrow Transplant. 2014;49:1439–1441.
   PubMed Web of Science ®Google Scholar
• Hartmann T, Hubel K, Monsef I, et al. Additional plerixafor to granulocyte colony-stimulating factors for haematopoetic stem cell mobilization for autologous transplantation in people with malignant lymphoma or multiple myeloma. Cochrane Database Syst Rev. 2015;10:CD010615. Oct 20.
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Gosole G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:719–724.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2003;44:815–820.
   PubMed Web of Science ®Google Scholar
• Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin’s lymphoma patients with ‘poor’ mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant. 2000;6:506–512.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance. Leuk Lymphoma. 2016 Jan 14;1–8. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Cooper DL, Pratt K, Baker J, et al. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clin Lymphoma Myeloma Leuk. 2011;11:267–272.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Mauge L, Rea D, et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of apheresis procedure. Transfusion. 2013;53:564–569.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Mahlamäki E, et al. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol. 2011 Apr;86(4):299–304.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Kramer C, Hogan KR, et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of pre-emptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012;52:2375–2381.
   PubMed Web of Science ®Google Scholar
• Herbert KE, Demosthenous L, Wiesner G, et al. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplant. 2014;49:1056–1062.
   PubMed Web of Science ®Google Scholar
• Karpova D, Dauber K, Spohn G, et al. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than plerixafor. Leukemia. 2013;27:2322–2331.
   PubMed Web of Science ®Google Scholar
• Peled A, Abraham M, Avivi I, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20:469–479.
   PubMed Web of Science ®Google Scholar